Grifols (GIKLY) Other Non-Current Liabilities (2009 - 2025)
Grifols (GIKLY) posted Other Non-Current Liabilities of $138.5 million for Q4 2025, up 12862.92% quarter-over-quarter from $1.1 million in Q4 2024, and up 12862.92% year-on-year from N/an in Q4 2024.
Grifols (GIKLY) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Other Non-Current Liabilities for 16 consecutive years, with $138.5 million the latest figure, recorded in Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $138.5 million, up 12862.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $138.5 million (up 12862.92% YoY), and the FY2025 annual result was $138.5 million, up 12862.92% from the prior year.
- Other Non-Current Liabilities was $138.5 million for Q4 2025 at Grifols, up from $1.1 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $138.5 million in Q4 2025 and troughed at $1.1 million in Q4 2024.
- Average Other Non-Current Liabilities over 5 years is $81.1 million, with a median of $112.3 million recorded in 2022.
- Year-over-year, Other Non-Current Liabilities plunged 99.15% in 2024 and soared 12862.92% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $27.6 million in 2021, then surged by 306.93% to $112.3 million in 2022, then increased by 12.03% to $125.8 million in 2023, then slumped by 99.15% to $1.1 million in 2024, then jumped by 12862.92% to $138.5 million in 2025.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $138.5 million in Q4 2025, $1.1 million in Q4 2024, and $125.8 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138.52 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 125.80 Mn |
| Dec 31, 2022 | 112.29 Mn |
| Dec 31, 2021 | 27.59 Mn |
| Dec 31, 2020 | 32.51 Mn |
| Sep 30, 2020 | 661.48 Mn |
| Mar 31, 2020 | 543.55 Mn |
| Dec 31, 2019 | 8.89 Mn |
| Sep 30, 2019 | 497.08 Mn |
| Dec 31, 2018 | 6.98 Mn |
| Sep 30, 2018 | 500.18 Mn |
| Jun 30, 2018 | 96.90 Mn |
| Mar 31, 2018 | 529.17 Mn |
| Dec 31, 2017 | 6.79 Mn |
| Jun 30, 2017 | 85.29 Mn |
| Dec 31, 2016 | 5.53 Mn |
| Sep 30, 2016 | 97.13 Mn |
| Jun 30, 2016 | 132.34 Mn |
| Dec 31, 2015 | 5.46 Mn |